Uveitis in Patients Treated with CTLA-4 and PD-1 Checkpoint Blockade Inhibition

REFERENCES

• Smyth MJ, Dunn GP, Schreiber RD. Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity. Adv Immunol. 2006;90:1–50. doi:10.1016/S0065-2776(06)90001-7.
   PubMed Web of Science ®Google Scholar
• Iwai Y, Hamanishi J, Chamoto K, Honjo T. Cancer immunotherapies targeting the PD-1 signaling pathway. J Biomed Sci. 2017;24(1):26. doi:10.1186/s12929-017-0329-9.
   PubMedGoogle Scholar
• Sweis RF, Luke JJ. Cutting the brakes: immunotherapy with PD-1 inhibitors. Clin. Skin Cancer 2017;2(1–2):24–31. doi:10.1016/j.clsc.2017.09.001.
   Google Scholar
• Granier C, De Guillebon E, Blanc C, et al. Mechanisms of action and rationale for the use of checkpoint inhibitors in cancer. ESMO Open. 2017;2(2):e000213. doi:10.1136/esmoopen-2017-000213.
   PubMed Web of Science ®Google Scholar
• Zamani MR, Aslani S, Salmaninejad A, Javan MR, Rezaei N. PD-1/PD-L and autoimmunity: a growing relationship. Cell Immunol. 2016;310:27–41. doi:10.1016/j.cellimm.2016.09.009.
   PubMed Web of Science ®Google Scholar
• Abdel-Wahab N, Alshawa A, Suarez-Almazor ME. Adverse events in cancer immunotherapy. In: Naing A, Hajjar J, eds. Immunotherapy. Advances in Experimental Medicine and Biology. Vol. 995. Cham, Switzerland: Springer International Publishing; 2017:155–174. doi:10.1007/978-3-319-53156-4_8.
   Google Scholar
• Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–723. doi:10.1056/NEJMoa1003466.
   PubMed Web of Science ®Google Scholar
• Michot JM, Bigenwald C, Champiat S, et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer. 2016;54:139–148. doi:10.1016/j.ejca.2015.11.016.
   PubMed Web of Science ®Google Scholar
• Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443–2454. doi:10.1056/NEJMoa1200690.
   PubMed Web of Science ®Google Scholar
• Brahmer JR, Tykodi SS, Chow LQM, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366(26):2455–2465. doi:10.1056/NEJMoa1200694.
   PubMed Web of Science ®Google Scholar
• Abdel-Wahab N, Shah M, Suarez-Almazor ME, Nishikawa H. Adverse events associated with immune checkpoint blockade in patients with cancer: a systematic review of case reports. Nishikawa H, ed. PLoS One. 2016;11(7):e0160221. doi:10.1371/journal.pone.0160221.
   PubMed Web of Science ®Google Scholar
• Hamid O, Robert C, Daud A, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med. 2013;369(2):134–144. doi:10.1056/NEJMoa1305133.
   PubMed Web of Science ®Google Scholar
• Ribas A, Puzanov I, Dummer R, et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol. 2015;16(8):908–918. doi:10.1016/S1470-2045(15)00083-2.
   PubMed Web of Science ®Google Scholar
• Ribas A, Hamid O, Daud A, et al. Association of pembrolizumab with tumor response and survival among patients with advanced melanoma. JAMA. 2016;315(15):1600–1609. doi:10.1001/jama.2016.4059.
   PubMed Web of Science ®Google Scholar
• Robert C, Ribas A, Wolchok JD, et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet. 2014;384(9948):1109–1117. doi:10.1016/S0140-6736(14)60958-2.
   PubMed Web of Science ®Google Scholar
• Abdel-Rahman O, Oweira H, Petrausch U, et al. Immune-related ocular toxicities in solid tumor patients treated with immune checkpoint inhibitors: a systematic review. Expert Rev Anticancer Ther. 2017;17(4):387–394. doi:10.1080/14737140.2017.1296765.
   PubMed Web of Science ®Google Scholar
• Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013;369(2):122–133. doi:10.1056/NEJMoa1302369.
   PubMed Web of Science ®Google Scholar
• Hammers HJ, Plimack ER, Sternberg C, et al. CheckMate 214: a phase III, randomized, open-label study of nivolumab combined with ipilimumab versus sunitinib monotherapy in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol. 2015;33(15_suppl):TPS4578–TPS4578. doi:10.1200/jco.2015.33.15_suppl.tps4578.
   Web of Science ®Google Scholar
• Jabs DA, Nussenblatt RB, Rosenbaum JT, Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the first international workshop. AJOPHT. 2005;140(3):509–516 http://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=16196117&retmode=ref&cmd=prlinks
   Google Scholar
• Chan PY, Hall P, Hay G, Cohen VML, Szlosarek PW. A major responder to ipilimumab and nivolumab in metastatic uveal melanoma with concomitant autoimmunity. Pigment Cell Melanoma Res. 2017;17(4):387. doi:10.1111/pcmr.12607.
   Google Scholar
• Kanno H, Ishida K, Yamada W, et al. Uveitis induced by programmed cell death protein 1 inhibitor therapy with nivolumab in metastatic melanoma patient. J Infect Chemother. 2017;May. doi:10.1016/j.jiac.2017.04.007.
   Google Scholar
• Matsuo T, Yamasaki O. Vogt-Koyanagi-Harada disease-like posterior uveitis in the course of nivolumab (anti-PD-1 antibody), interposed by vemurafenib (BRAF inhibitor), for metastatic cutaneous malignant melanoma. Clin Case Rep. 2017;5(5):694–700. doi:10.1002/ccr3.911.
   PubMed Web of Science ®Google Scholar
• Arai T, Harada K, Usui Y, Irisawa R, Tsuboi R. Case of acute anterior uveitis and Vogt-Koyanagi-Harada syndrome-like eruptions induced by nivolumab in a melanoma patient. J Dermatol. 2016;16:375. doi:10.1111/1346-8138.13612.
   Google Scholar
• Karlin J, Gentzler R, Golen J. Bilateral anterior uveitis associated with nivolumab therapy. Ocul Immunol Inflamm. 2017;374:1–3. doi:10.1080/09273948.2016.1215473.
   Google Scholar
• de Velasco G, Bermas B, Choueiri TK. Autoimmune arthropathy and uveitis as complications of programmed death 1 inhibitor treatment. Arthritis Rheumatol. 2016;68(2):556–557. doi:10.1002/art.39406.
   PubMed Web of Science ®Google Scholar
• Richardson DR, Ellis B, Mehmi I, Leys M. Bilateral uveitis associated with nivolumab therapy for metastatic melanoma: a case report. Int J Ophthalmol. 2017;10(7):1183–1186. doi:10.18240/ijo.2017.07.28.
   PubMed Web of Science ®Google Scholar
• Baughman DM, Lee CS, Snydsman BE, Jung HC Bilateral uveitis and keratitis following nivolumab treatment for metastatic melanoma. Med Case Rep (Wilmington). 2017;3(2). doi:10.21767/2471-8041.100044.
   PubMedGoogle Scholar
• Theillac C, Straub M, Breton A-L, Thomas L, Dalle S. Bilateral uveitis and macular edema induced by Nivolumab: a case report. BMC Ophthalmol. 2017;17(1):227. doi:10.1186/s12886-017-0611-3.
   PubMedGoogle Scholar
• Gonzales JA, Shantha J, Acharya NR. Combination nivolumab- and cabiralizumab-associated acute bilateral anterior and posterior scleritis and anterior uveitis. Am J Ophthalmol Case Rep. 2018;10:117–118. doi:10.1016/j.ajoc.2018.02.005.
   PubMedGoogle Scholar
• Fujimura T, Kambayashi Y, Tanita K, et al. HLA-DRB1*04:05 in two cases of Vogt-Koyanagi-Harada disease-like uveitis developing from an advanced melanoma patient treated by sequential administration of nivolumab and dabrafenib/trametinib therapy. J Dermatol. 2018;45(6):735–737. doi:10.1111/1346-8138.14273.
   PubMed Web of Science ®Google Scholar
• Lise Q-K, Audrey A-G. Multifocal choroiditis as the first sign of systemic sarcoidosis associated with pembrolizumab. Am J Ophthalmol Case Rep. 2017;5:92–93. doi:10.1016/j.ajoc.2016.12.014.
   PubMedGoogle Scholar
• Hanna KS. A rare case of pembrolizumab-induced uveitis in a patient with metastatic melanoma. Pharmacotherapy. 2016;36(11):e183–e188. doi:10.1002/phar.1839.
   PubMed Web of Science ®Google Scholar
• Abu Samra K, Valdes-Navarro M, Lee S, Swan R, Foster CS, Anesi SD. A case of bilateral uveitis and papillitis in a patient treated with pembrolizumab. Eur J Ophthalmol. 2016;26(3):e46–e48. doi:10.5301/ejo.5000724.
   PubMed Web of Science ®Google Scholar
• Taylor SC, Hrisomalos F, Linette GP, Rao PK. A case of recurrent bilateral uveitis independently associated with dabrafenib and pembrolizumab therapy. Am J Ophthalmol Case Rep. 2016;2:23–25. doi:10.1016/j.ajoc.2016.04.004.
   PubMedGoogle Scholar
• Aaberg MT, Aaberg TM Jr. PEMBROLIZUMAB ADMINISTRATION ASSOCIATED WITH POSTERIOR UVEITIS. Retin Cases Brief Rep. 2016 August:1. doi:10.1097/ICB.0000000000000368.
   PubMedGoogle Scholar
• Basilious A, Lloyd JC. Posterior subcapsular cataracts and hypotony secondary to severe pembrolizumab induced uveitis: case report. Can J Ophthalmol. 2016;51(1):e4–e6. doi:10.1016/j.jcjo.2015.09.008.
   PubMed Web of Science ®Google Scholar
• Diem S, Keller F, Rüesch R, et al. Pembrolizumab-triggered Uveitis. J Immunother. 2016;39(9):379–382. doi:10.1097/CJI.0000000000000143.
   PubMed Web of Science ®Google Scholar
• Bricout M, Petre A, Amini-Adle M, et al. Vogt-Koyanagi-Harada-like syndrome complicating pembrolizumab treatment for metastatic melanoma. J Immunother. 2017;40(2):77–82. doi:10.1097/CJI.0000000000000154.
   PubMed Web of Science ®Google Scholar
• Reid G, Lorigan P, Heimann H, Hovan M. Management of chronic hypotony following bilateral uveitis in a patient treated with pembrolizumab for cutaneous metastatic melanoma. Ocul Immunol Inflamm. 2018 April:1–4. doi:10.1080/09273948.2018.1459733.
   PubMed Web of Science ®Google Scholar
• Wong RK, Lee JK, Huang JJ. Bilateral drug (ipilimumab)-induced vitritis, choroiditis, and serous retinal detachments suggestive of vogt-koyanagi-harada syndrome. Retin Cases Brief Rep. 2012;6(4):423–426. doi:10.1097/ICB.0b013e31824f7130.
   PubMedGoogle Scholar
• Norose K, Yano A. Melanoma specific Th1 cytotoxic T lymphocyte lines in Vogt-Koyanagi-Harada disease. Br J Ophthalmol. 1996;80:1002–1008.
   PubMed Web of Science ®Google Scholar
• Lavezzo MM, Sakata VM, Morita C, et al. Vogt-Koyanagi-Harada disease: review of a rare autoimmune disease targeting antigens of melanocytes. Orphanet J Rare Dis. 2016;11(1):29. doi:10.1186/s13023-016-0412-4.
   PubMedGoogle Scholar
• Shi T, Lv W, Zhang L, Chen J, Chen H. Association of HLA-DR4/HLA-DRB1*04 with Vogt-Koyanagi-Harada disease: a systematic review and meta-analysis. Sci Rep. 2014;4(1):6887. doi:10.1038/srep06887.
   PubMedGoogle Scholar
• Aisenbrey S, Lüke C, Ayertey HD, Grisanti S, Perniok A, Brunner R. Vogt-Koyanagi-Harada syndrome associated with cutaneous malignant melanoma: an 11-year follow-up. Graefes Arch Clin Exp Ophthalmol. 2003;241(12):996–999. doi:10.1007/s00417-003-0787-5.
   PubMed Web of Science ®Google Scholar
• Caspi RR. Immunotherapy of autoimmunity and cancer: the penalty for success. Nat Rev Immunol. 2008;8(12):970–976. doi:10.1038/nri2438.
   PubMed Web of Science ®Google Scholar
• Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(1):23–34. doi:10.1056/NEJMoa1504030.
   PubMed Web of Science ®Google Scholar
• Robert C, Schachter J, Long GV, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372(26):2521–2532. doi:10.1056/NEJMoa1503093.
   PubMed Web of Science ®Google Scholar
• Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372(4):320–330. doi:10.1056/NEJMoa1412082.
   PubMed Web of Science ®Google Scholar
• Yeh S, Karne NK, Kerkar SP, et al. Ocular and systemic autoimmunity after successful tumor-infiltrating lymphocyte immunotherapy for recurrent, metastatic melanoma. Ophthalmology. 2009;116(5):981–989.e981. doi:10.1016/j.ophtha.2008.12.004.
   PubMed Web of Science ®Google Scholar
• Palmer DC, Chan CC, Gattinoni L, et al. Effective tumor treatment targeting a melanoma/melanocyte-associated antigen triggers severe ocular autoimmunity. Proc Natl Acad Sci USA. 2008;105(23):8061–8066. doi:10.1073/pnas.0710929105.
   PubMed Web of Science ®Google Scholar
• Chen TW, Razak AR, Bedard PL, Siu LL, Hansen AR. A systematic review of immune-related adverse event reporting in clinical trials of immune checkpoint inhibitors. Ann Oncol. 2015;26(9):1824–1829. doi:10.1093/annonc/mdv182.
   PubMed Web of Science ®Google Scholar
• Gao J, He Q, Subudhi S, et al. Review of immune-related adverse events in prostate cancer patients treated with ipilimumab: MD Anderson experience. Oncogene. 2015;34(43):5411–5417. doi:10.1038/onc.2015.5.
   PubMed Web of Science ®Google Scholar
• Kadono T. Immune-related adverse events by immune checkpoint inhibitors. Nihon Rinsho Meneki Gakkai Kaishi. 2017;40(2):83–89. doi:10.2177/jsci.40.83.
   PubMedGoogle Scholar
• Dalvin LA, Shields CL, Orloff M, Sato T, Shields JA. Checkpoint Inhibitor Immune Therapy: systemic indications and ophthalmic side effects. Retina (Philadelphia, Pa). 2018;38(6):1063–1078. doi:10.1097/IAE.0000000000002181.
   PubMed Web of Science ®Google Scholar
• Trusko B, Thorne J, Jabs D, et al. The Standardization of Uveitis Nomenclature (SUN) project. Development of a clinical evidence base utilizing informatics tools and techniques. Methods Inf Med. 2013;52(3): 259–65–S1–6. doi:10.3414/ME12-01-0063.
   PubMed Web of Science ®Google Scholar